Recent advances in radiation therapy of pancreatic cancer
Open Access
- 13 December 2018
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 7, 1931
Abstract
Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agents, radiation therapy (RT) techniques, and immunotherapy paradigms. RT dose, modality, fraction size, and sequencing are being evaluated actively, and the interplay between RT and immune effects has opened up newer avenues of research. In this review, we will emphasize recent advances in RT for pancreatic cancer, focusing on preoperative chemoradiation, RT dose escalation, sparing of the spleen to reduce lymphopenia, and combination of RT with immunotherapy.Keywords
Funding Information
- University of Texas MD Anderson Cancer Center (JohnE.andDorothyJ.HarrisEndowedProfessorship)
- MD Anderson Cancer Center Support Grant (P30 CA16672)
- MD Anderson Cancer Center Support Grant (U01CA216468)
This publication has 65 references indexed in Scilit:
- The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the PancreasCancer Investigation, 2012
- Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancerRadiation Oncology, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals of Oncology, 2008
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- Surgical treatment of pancreatic adenocarcinomaEuropean Journal of Cancer, 2004
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993